Estrella Immunopharma Warrant
ESLAW
13 hedge funds and large institutions have $2.59M invested in Estrella Immunopharma Warrant in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 13 → 13 (0)
6% less capital invested
Capital invested by funds: $2.75M → $2.59M (-$157K)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EFI
EHP Funds Inc
Toronto,
Canada
|
+$3.42K |
| 2 |
CS
Clear Street
New York
|
+$2.99K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$4K |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$85 |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$33 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFM
1
Boothbay Fund Management
New York
| $2.03M | – | – | – |
|
|
RCM
2
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
| $503K | – | – | – |
|
|
ASM
3
ATW SPAC Management
New York
| $13K | – | – | – |
|
|
EFI
4
EHP Funds Inc
Toronto,
Canada
| $13K | +$3.42K | +20,210 | +12% |
|
|
KPF
5
K2 Principal Fund
Toronto,
Ontario, Canada
| $10K | – | – | – |
|
|
CH
6
CVI Holdings
Wilmington,
Delaware
| $6K | – | – | – |
|
7
D.E. Shaw & Co
New York
| $6K | – | – | – |
|
|
8
Hudson Bay Capital Management
Stamford,
Connecticut
| $4K | -$4K | -23,671 | -31% |
|
|
WA
9
Whitebox Advisors
Minneapolis,
Minnesota
| $3K | – | – | – |
|
|
10
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $2K | -$33 | -193 | -0.7% |
|
|
SSA
11
Schonfeld Strategic Advisors
New York
| $1K | -$85 | -500 | -3% |
|
|
CS
12
Clear Street
New York
| $1K | +$2.99K | +17,650 | +17,650% |
|
ESLAW Hedge Fund Activity: Q3 2022 in Review
13 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma Warrant (ESLAW) for Q3 2022, worth a combined $2.59M — down 5.7% from $2.75M a quarter earlier.
Fund positioning in ESLAW was balanced in Q3 2022: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 3 trimmed.
The largest buyer was EHP Funds Inc, adding an estimated $3.42K. The largest seller was Hudson Bay Capital Management, cutting an estimated $4K.
- 13 institutional investors held Estrella Immunopharma Warrant (ESLAW) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $2.59M of Estrella Immunopharma Warrant stock for Q3 2022, down 5.7% quarter-over-quarter.
- 0 funds opened new Estrella Immunopharma Warrant positions in Q3 2022 and 0 closed out.
- The largest Estrella Immunopharma Warrant buyer in Q3 2022 was EHP Funds Inc, an estimated $3.42K added.
- The largest Estrella Immunopharma Warrant seller in Q3 2022 was Hudson Bay Capital Management, an estimated $4K sold.
Based on aggregated 13F filings for Q3 2022.